Abstract:
The present invention relates to a drug delivery system and uses thereof. Specifically, a system that can be used to deliver therapeutic proteins, including antibodies, to proteolytic environments is disclosed. In one form of the invention the drug delivery system is a composition which comprises a porous substrate and an antibody bound to the substrate. In one embodiment, the composition comprises nanoporous silicon and can be used to deliver antibodies for the treatment, or for improving the repair, of a wound.
Abstract:
Methods and apparatus for communication between terminals and an access node in a multiuser multicarrier communications network are described. The access node may be a satellite access node. Terminals are configured to perform initial estimation and tracking of channel offsets and to estimate channel offsets for future packets to be transmitted by the terminal. In some embodiments the channel offsets comprise mobility related channel offsets due to the relative movement between the access node and the plurality of terminals. Transmissions from the terminals to the access node are pre-compensated for the channel offsets, so that the aggregate signal received by the access node occupies a bandwidth greater or equal to the maximum signal bandwidth of any individual terminal. Terminal transmissions may overlap in frequency and time on the ground, but arrive orthogonally at the access node.
Abstract:
This disclosure relates to a process for selectively extracting Fe(III) ions from an aqueous feedstock containing Fe(III) ions and non-ferric ions. The process comprises contacting the feedstock with an organic phase comprising a phosphonium salt or ammonium salt ionic liquid under liquid-liquid extraction conditions for a time sufficient to allow transfer of at least some of the Fe(III) ions from the feedstock to the organic phase to provide an Fe(III) ion laden organic phase and an Fe(III) depleted feed-stock, and separating the Fe(III) ion laden organic phase from the Fe(III) depleted feedstock.
Abstract:
The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.
Abstract:
Disclosed herein is a plasma treatment method comprising: providing a plasma source and a screen comprising a hydrogel and positioning the screen between the plasma source and a surface of a target to be treated with the plasma such that substantially all of the plasma from the plasma source passes through the screen prior to contacting the surface of the target and the screen reduces the concentration of one or more species from the plasma; and/or contacting a surface of a target to be treated with the gel composition comprising a gel forming material and a liquid phase comprising plasma activated liquid.
Abstract:
User input gloves and input methods are described that are well suited to provide input to computer modeling (eg CAD) and augmented reality (AR) systems, including wearable AR and spatial AR. Each glove comprises palm mounted ultrasonic transducers, accelerometers, finger based pinch inputs and a wireless communication module. The gloves can be used to measure distances over the natural range of distances that hands can be placed, as well as their orientation, with sufficient resolution to facilitate a range of gesture based input methods to be developed and utilized, including distance-based modeling by measurement. Further the gloves are light weight, allow fast input of modeling measurements, are easy to use, and reduce fatigue compared to existing glove based input systems. The user input gloves, and associated input techniques can be used to measure small and body sized objects using one or two hands, and large objects can be measured using single handed measurements. Further models for both small and large objects can be generated and manipulated through the use of a numeric input technique to obtain an amplification factor to magnify the effective distances measured.
Abstract:
The invention relates to method and apparatus for improving the performance of communication systems using Run Length Limited (RLL) messages such as the existing Automatic Identification System (AIS). A binary data sequence is Forward Error Correction (FEC) coded and then the sequence is compensated, for example by bit-erasure, so that either bit-stuffing is not required, or a bit stuffer will not be activated to ensure that the coded sequence meets the RLL requirement. Various embodiments are described to handle different architectures or input points for the FEC encoder and bit erasure module. The bit erasure module may also add dummy bits to ensure a RLL compliant CRC or to selectively add bits to a reserve buffer to compensate for later bit stuffing in a header. Additional RLL training sequences may also be added to assist in, receiver acquisition.
Abstract:
The present disclosure relates to methods for detecting a prostate cancer. Certain embodiments of the present disclosure provide a method of detecting a prostate cancer in a subject, the method comprising detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.
Abstract:
The present invention relates to a polymeric substrate being coated with a reflective coating, particularly a chromium-based reflective coating.
Abstract:
The present invention provides a method of producing a multipotent stem cell, said method comprising culturing at least one fibroblast cell in the presence of an effective amount of at least one small molecule reprogramming factor(s) that induces the cell to de-differentiate into a multipotent stem cell, wherein the method excludes the use of reprogramming factor(s) that are not small molecules. The small molecule reprogramming factor(s) may include a G9a HMTase inhibitor(s) and/or a MEK inhibitor(s) optionally in combination with other small molecule reprogramming factor(s). The invention also includes methods of differentiating the multipotent stem cells, cells produced by the methods, assays using the cells and kits for use in the methods.